CXCL1 and gastric adenocarcinoma: CXCL1 and CXCL2 are 90% identical by amino acid sequence and signal through the same receptor, CXCR2.[32] Therefore, further studies should be performed to verify whether CXCL2 could act as a biomarker for drug screening in STAD.